Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated ...

A new thesis from Karolinska Institutet aims to advance our understanding of the bidirectional relationship between ...

The mechanism of action of ABX464 is triggered ... for induction treatment of moderate-to-severe ulcerative colitis (UC), with patients who failed on immunomodulators, anti-TNFα, vedolizumab ...

AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

New Understanding of the Gut Immune System May Hold Promise for Crohn's Disease Patients Mar. 15, 2024 — Scientists uncovered an overlooked mechanism in the gut immune system of patients ...

Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

Ulcerative colitis is a chronic relapsing and remitting inflammatory disorder that can generally be managed successfully with maintenance oral medications. However, approximately 15% of patients ...